TORONTO, Oct. 30 /CNW/ - McVicar Resources Inc. ("McVicar") is pleased to announce that its Chinese subsidiary, Zhejiang Hongbo Chemical Co. Ltd. ("Hongbo") has received an initial order for its intermediate chemicals used in anti-AIDS drugs from a major pharmaceutical company in South Korea. The order valued at approximately 5 million RMB calls for the immediate delivery of 6,000 kg of the intermediate chemical. The South Korean company also expressed its intention to purchase a further 5,000 kg of the intermediate chemical for future delivery.

    "We are extremely excited about this breakthrough order of Hongbo's intermediate chemicals used in anti-AIDS drugs. This marks the company's successful penetration into a large, global market. Hongbo has been relying on research from one of China's top research institutes, the Shanghai Institute of Organic Chemistry, to develop its products through a collaborative relationship. As a result of the company's focus on R&D, and its dedication to product quality, Hongbo has obtained numerous international orders in recent months", commented Dr. Gang Chai, President & CEO of McVicar, "This order is only the beginning of our multiple product offerings. We believe that the high standard of quality and low cost products will continue to further attract international orders."

    On Sept. 7, 2007, McVicar Resources Inc. announced that Hongbo had signed a long-term supply contract with Dupont valued at US$20 million. This contract followed an order from Dupont in June 2007, valued at US$1.78 million. More recently, on Sept. 20, 2007, Hongbo received an order valued at US$800,000 from a major South Korean company.

    Zhejiang Hongbo Chemical Co. Ltd. is a wholly owned Chinese subsidiary of McVicar (Hongkong) Advanced Material Co. Ltd. which is 51% owned by McVicar Resources Inc.

    This press release contains forward-looking statements which reflect the Corporation's current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual results could differ materially from those projected herein. Although we believe that our expectations are based on reasonable assumptions, we can give no assurance that our expectations will materialize.

    The TSX Venture Exchange does not accept responsibility for the adequacy     or accuracy of this release.

For further information: Dr. Gang Chai at: 55 University Avenue, Suite 605, Toronto, ON, M5J 2H7, Tel: (416) 366-7420, Fax (416) 366-7421, www.mcvicar.ca